LMNL

Liminal BioSciences Inc. [LMNL] Stock Forecast

Q: What is Liminal BioSciences Inc. stock symbol ?

Liminal BioSciences Inc. is a CA stock, located in Laval of Qc and trading under the symbol LMNL

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LMNL Stock Summary

Earnings are expected to rise 411.25% next year

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Does not have any significance market cap ($12.05M)

Profit margins (-29.17%) are lower than the previous year (20.03%)

LMNL has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

LMNL

Top 10 Correlated Stocks

LMNL

In the News

04:08 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q4 2022 Results Conference Call March 16, 2023 8:30 AM ET Company Participants Shrinal Inamdar - IR Bruce Pritchard - CEO Nicole Rusaw - CFO Conference Call Participants Antonia Borovina - Bloom Burton Operator Good morning, ladies and gentlemen, and welcome to the Liminal BioSciences, Inc. Fourth Quarter 2022 Results [Foreign Language] Conference Call. [Operator Instructions] This call is being recorded on Thursday, March 16, 2023.

04:38 26 Mar 2023 LMNL

Liminal BioSciences to Present at BIO CEO & Investor Conference

LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Tuesday February 7, 2023 at 10:30am (ET) during the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023. The Company will be available for meetings with conference attendees.

10:17 26 Mar 2023 LMNL

Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript

Liminal Biosciences (NASDAQ:LMNL ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Operator Good day and welcome to the Liminal Biosciences Third Quarter 2022 Results conference call. At this time, I would like to turn the call over to Shrinal.

03:22 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.

08:30 26 Mar 2023 LMNL

Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).

06:52 26 Mar 2023 LMNL

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.

04:54 26 Mar 2023 LMNL

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

04:10 26 Mar 2023 LMNL

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million.

08:46 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript

09:19 26 Mar 2023 LMNL

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LMNL Financial details

Company Rating

Strong Buy

Market Cap

12.05M

Income

500K

Revenue

401K

Book val./share

1.3

Cash/share

1.31

Dividend

Dividend %

Employees

251

Optionable

Shortable

Yes

Earnings

08 May 2023

P/E

-10.38

Forward P/E

PEG

1.08

P/S

302.87

P/B

2.98

P/C

2.96

P/FCF

-0.31

Quick Ratio

4.63

Current Ratio

4.85

Debt / Equity

0.33

LT Debt / Equity

0.02

EPS (TTM)

0.02

EPS next Y

EPS next Q

-0.5

EPS this Y

274.65%

EPS next Y

EPS next 5Y

-81929.35%

EPS last 5Y

NAN%

Revenue last 5Y

-61.49%

Revenue Q/Q

7933.33%

EPS Q/Q

-122.26%

SMA20

-23.72%

SMA50

19.77%

SMA100

-20.83%

Inst Own

0.59%

Inst Trans

-0.06%

ROA

-22%

ROE

-32%

ROC

-0.8%

Gross Margin

Oper. Margin

-8976%

Profit Margin

-2917%

Payout

Shs Outstand

3.1M

Shs Float

1.11M

Target Price

52W Range

3.1-10.9

52W High

-61.17%

52W Low

+29.44%

RSI

25.73

Rel Volume

0.14

Avg Volume

8.46K

Volume

1.21K

Perf Week

-14.09%

Perf Month

-29.65%

Perf Quarter

-7.55%

Perf Half Y

-13.98%

Beta

30.7745

Volatility

0.16%, 0.67%

Prev Close

1.92%

Price

3.8831

Change

1.92%

LMNL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	57.19	66.15	0.31	0.14	0.02
Net income per share	-160.44	-272.78	-12.81	-4.83	0.43
Operating cash flow per share	-179.21	-115.13	-6.19	-3.11	-3.3
Free cash flow per share	-193.95	-122.29	-6.46	-3.19	-3.32
Cash per share	33.87	10.32	3.82	1.84	3.6
Book value per share	178.35	-79.03	6.36	0.95	1.41
Tangible book value per share	-19.32	-115.82	5.05	-0.02	1.01
Share holders equity per share	178.35	-79.03	6.36	0.95	1.41
Interest debt per share	147.19	217.63	3.81	3.38	2.22
Market cap	8.91B	1.9B	1.76B	1.31B	419.02M
Enterprise value	8.98B	2.03B	1.74B	1.34B	371.31M
P/E ratio	-81.18	-9.74	-8.55	-11.1	32.53
Price to sales ratio	227.74	40.16	358.47	394.55	651.66
POCF ratio	-72.67	-23.07	-17.69	-17.24	-4.21
PFCF ratio	-67.15	-21.72	-16.93	-16.79	-4.19
P/B Ratio	73.02	-33.61	17.2	56.66	9.83
PTB ratio	73.02	-33.61	17.2	56.66	9.83
EV to sales	229.51	42.82	355.57	403.27	577.47
Enterprise value over EBITDA	-80.42	-10.82	-9.58	-13.25	15.68
EV to operating cash flow	-73.24	-24.6	-17.54	-17.62	-3.73
EV to free cash flow	-67.67	-23.16	-16.79	-17.16	-3.71
Earnings yield	-0.01	-0.1	-0.12	-0.09	0.03
Free cash flow yield	-0.01	-0.05	-0.06	-0.06	-0.24
Debt to equity	1.15	-2.93	0.69	4.45	2.16
Debt to assets	0.49	1.61	0.42	0.87	0.73
Net debt to EBITDA	-0.62	-0.67	0.08	-0.29	-2.02
Current ratio	2.01	1.14	3.03	3.07	6.2
Interest coverage	-14.9	-5.09	-8.41	-10.79	-7.84
Income quality	1.12	0.42	0.48	0.64	-7.73
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	2.57	1.93	15.32	17.13	28.53
Intangibles to total assets	0.55	0.19	0.08	0.13	0.03
Capex to operating cash flow	0.08	0.06	0.04	0.03	0
Capex to revenue	-0.26	-0.11	-0.91	-0.62	-0.72
Capex to depreciation	-2.2	-0.94	-0.45	-0.24	-0.11
Stock based compensation to revenue	0.22	0.14	4.41	1.87	6.58
Graham number	802.38	696.47	42.82	10.13	3.69
ROIC	-0.5	-1.57	-3.69	-5.08	0.51
Return on tangible assets	-0.86	-2.35	-1.36	-1.15	0.11
Graham Net	-133.13	-192.2	0.3	-2.05	0.57
Working capital	36.26M	5.11M	63.59M	49.24M	96.14M
Tangible asset value	-13.22M	-82.95M	81.09M	-480K	30.37M
Net current asset value	-68.17M	-125.2M	24.69M	-29.75M	22.46M
Invested capital	0.76	-2.36	0.46	3.2	1.43
Average receivables	9.87M	15.46M	16.64M	8.6M	2.49M
Average payables	16.8M	20.22M	15.8M	9.82M	7.46M
Average inventory	24.84M	24.02M	9.78M	8.45M	4.69M
Days sales outstanding	102.23	153.88	989.91	429.48	606.25
Days payables outstanding	695.29	202.63	1.39K	1.64K	0
Days of inventory on hand	1.3K	115.53	995	1.68K	0
Receivables turnover	3.57	2.37	0.37	0.85	0.6
Payables turnover	0.52	1.8	0.26	0.22	0
Inventory turnover	0.28	3.16	0.37	0.22	0
ROE	-0.9	3.45	-2.01	-5.11	0.3
Capex per share	-14.74	-7.16	-0.28	-0.08	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0.01	0	0	0.01	0
Net income per share	2.74	-0.21	-0.34	-0.19	0.71
Operating cash flow per share	-1.91	-0.16	-0.23	-0.22	-0.38
Free cash flow per share	-1.91	-0.16	-0.23	-0.22	-0.38
Cash per share	3.9	1.35	1.97	1.8	1.31
Book value per share	1.88	0.53	1.05	0.88	1.3
Tangible book value per share	1.46	0.38	0.75	0.57	1.3
Share holders equity per share	1.88	0.53	1.05	0.88	1.3
Interest debt per share	2.17	0.78	0.78	0.77	0.08
Market cap	871.74M	1.12B	384.24M	203.41M	178.29M
Enterprise value	818.21M	1.07B	345.79M	170.72M	139.1M
P/E ratio	2.65	-16.43	-9.06	-8.57	2.03
Price to sales ratio	5.13K	4.69K	0	1.3K	59.43K
POCF ratio	-15.25	-87.27	-54.54	-30.01	-15.24
PFCF ratio	-15.22	-87.22	-54.54	-29.97	-15.24
P/B Ratio	15.46	26.18	11.76	7.46	4.41
PTB ratio	15.46	26.18	11.76	7.46	4.41
EV to sales	4.81K	4.49K	0	1.09K	46.37K
Enterprise value over EBITDA	9.64	-73.76	-37.42	-35.62	6.01
EV to operating cash flow	-14.31	-83.54	-49.08	-25.19	-11.89
EV to free cash flow	-14.28	-83.49	-49.08	-25.16	-11.89
Earnings yield	0.09	-0.02	-0.03	-0.03	0.12
Free cash flow yield	-0.07	-0.01	-0.02	-0.03	-0.07
Debt to equity	1.77	2.16	1.65	1.95	0.33
Debt to assets	0.68	0.73	0.7	0.75	0.25
Net debt to EBITDA	-0.63	3.29	4.16	6.82	-1.69
Current ratio	6.21	6.2	2.77	2.35	4.85
Interest coverage	-7.58	-6.24	-6.82	-9.71	-8.26
Income quality	-0.7	0.75	0.66	1.14	-0.53
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	29.6	1.46K
Research and developement to revenue	29.25	19.07	0	25.11	1.17K
Intangibles to total assets	0.03	0.03	0	0	0.06
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	-0.76	-0.03	0	-0.05	-1
Capex to depreciation	-0.16	-0.01	0	-0.03	-0.01
Stock based compensation to revenue	10.37	2.62	0	3.42	137.67
Graham number	10.78	1.59	2.84	1.94	4.55
ROIC	0.17	0.11	0.17	0.21	0.29
Return on tangible assets	0.57	-0.14	-0.14	-0.08	0.43
Graham Net	0.6	0.21	0.26	0.12	0.91
Working capital	113.33M	96.14M	42.69M	35M	35.18M
Tangible asset value	43.63M	30.37M	23.35M	17.65M	37.1M
Net current asset value	35.35M	22.46M	12.97M	7.77M	30.82M
Invested capital	1.12	1.43	0.7	0.85	0.04
Average receivables	1.43M	1.14M	933.5K	1.14M	1.49M
Average payables	0	2.88M	6.93M	4.05M	0
Average inventory	0	0	0	0	0
Days sales outstanding	639.53	403.87	0	848.41	44.94K
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.14	0.22	0	0.11	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	1.46	-0.4	-0.32	-0.22	0.54
Capex per share	0	0	0	0	0

LMNL Frequently Asked Questions

What is Liminal BioSciences Inc. stock symbol ?

Liminal BioSciences Inc. is a CA stock , located in Laval of Qc and trading under the symbol LMNL

What is Liminal BioSciences Inc. stock quote today ?

Liminal BioSciences Inc. stock price is $3.8831 today.

Is Liminal BioSciences Inc. stock public?

Yes, Liminal BioSciences Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 8.46K
Market Capitalization 12.05M
Employee 251
CEO Mr. Bruce Pritchard BA, CA, FIOD
Headquarters Laval,QC,CA
IPO Date 1994-10-14
Website https://www.liminalbiosciences.com

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.